Receive Email Updates
Certified Licensing Professionals, Inc., 2021
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
- About Me
Warren D. Woessner
Tag Archives: Biosimilars
Sandoz Launches First Biosimilar Drug in U.S.
A new chapter in the generics/innovator wars began Thursday as Sandoz, Novartis’ generics division launched its Neupogen biosimilar, Zarxio, in the U.S. at about a 15-30% discount from the price of Neupogen. While biosimilars have been marketed in Europe since 2006, Congress … Continue reading
Posted in Biosimilars Tagged Biosimilars, biotechnology, biotechnology law, biotechnology news, intellectual property, ip, Novartis, Patent Law, patents, Sandoz, Warren Woessner, Zarxio Leave a comment
The “Top Ten” IP Stories of 2014 (Most “Definitely”)
I don’t think I can recall a more action-packed year for intellectual property law in my career, much less during the almost six years that I have been writing this blog. I am trying to write this while in transit, … Continue reading
FDA’s New Biosimilars Guidance
The following has been posted with the permission of their authors James E. Valentine and James C. Shehan of Hyman, Phelps & McNamara as part of their FDA Law Blog. *** August 09, 2014 FDA’s New Biosimilars Guidance Has Sponsors … Continue reading
FDA Accepts First Biosimilar Application for Review
In an important step forward for the introduction of “generic biological,” the FDA announced that it has accepted Sandoz’s application to market a generic version of Amgen’s Neupogen®, which stimulates white blood cell production. As you may recall, about two years … Continue reading
Posted in FDA Tagged Amgen, Biosimilars, biotechnology, biotechnology law, biotechnology news, FDA, intellectual property, ip, IP law tools, Neupogen, patents, Sandoz, Warren Woessner Leave a comment